• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Theses
  • Research Data
  • Projects
  • Organizations
  • Researchers
  • More
  • Collections
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial.
 

Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial.

Options
  • Details
  • Files
BORIS DOI
10.7892/boris.59178
Publisher DOI
10.1111/jdv.12627
PubMed ID
25069999
Description
BACKGROUND

Telangiectasias of the lower extremities are very common. There are no blinded, randomized, controlled clinical trials comparing laser modalities with the gold standard sclerotherapy, while the few available studies encompass small patients cohorts.

OBJECTIVE

This prospective, randomized, open-label trial compares the efficacy of sclerotherapy with polidocanol vs. long-pulsed neodymium-doped yttrium aluminium garnet (Nd:YAG) laser in the treatment of leg telangiectasias.

PATIENTS AND METHODS

Fifty-six female patients with primary leg telangiectasias and reticular veins (C1A or S Ep AS 1 PN ) were included in the study. One leg was randomly assigned to get treatment with the multiple synchronized long-pulsed Nd:YAG laser, while the other received foam sclerotherapy with polidocanol 0.5%. The patients were treated in two sessions at intervals of 6 weeks. The patients were evaluated by the handling physician after 6 weeks and 6 months. Two investigators assessed blindly at the end of the study the photographs for clearing of the vessels using a six-point scale from 1 (no change) to 6 (100% cleared). Patients reported about pain sensation and outcome satisfaction.

RESULTS

According to the handling dermatologist, at the last follow-up, there was an improvement of 30-40% with a median of 3 (IQR 2) and a good improvement of 50-70% with a median of 4 (IQR 2) after laser treatment and sclerotherapy respectively. In contrast, according to the blinded investigators, there was a median of 5 (IQR 1) with a very good improvement of >70% after both therapies. Improvement was achieved more quickly by sclerotherapy, although at the last follow-up visit there was no difference in clearance between the two groups as assessed by the blinded experts (P-value 0.84). The degree of patient's satisfaction was very good and similar with both therapeutic approaches. There was a significant difference (P-value 0.003) regarding pain perception between the types of therapy. Laser was felt more painful than sclerotherapy.

CONCLUSION

Telangiectasias of the lower extremities can be successfully treated with either synchronized long-pulsed Nd:YAG laser or sclerotherapy. The 1064-nm long-pulsed Nd:YAG laser is associated with more pain and is suitable especially in case of needle phobia, allergy to sclerosants and in presence of small veins with telangiectatic matting, while sclerotherapy can also treat the feeder veins.
Date of Publication
2014-07-28
Publication Type
Article
Subject(s)
600 Technology > 610 Medicine & health
Language(s)
en
Contributor(s)
Parlar, B
Blazek, Claudia Rosa
Universitätsklinik für Dermatologie
Cazzaniga, S
Naldi, L
Klötgen, Hans-Willhelm
Universitätsklinik für Dermatologie
Borradori, Luca
Universitätsklinik für Dermatologie
Büttiker, Urs
Universitätsklinik für Dermatologie
Additional Credits
Universitätsklinik für Dermatologie
Series
Journal of the European Academy of Dermatology and Venereology
Publisher
Blackwell
ISSN
0926-9959
Access(Rights)
restricted
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: dd892c [ 9.04. 8:30]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
  • Events
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo